Hedge Funds Surface in Wave of Biopharma SPAC Deals

RTW and Perceptive Advisors are among investors seen in recent SPAC deals in biopharma.

 Joseph Edelman, CEO of Perceptive Advisors. (Chris Goodney/Bloomberg)

Joseph Edelman, CEO of Perceptive Advisors.

(Chris Goodney/Bloomberg)

The rise of special purpose acquisition companies is giving investors in private companies a public avenue to exit their deals.

SPACs, or blank check companies designed to buy businesses and instantly take them public, tend to be less expensive and faster than initial public offerings.

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.

Related